{
  "docId": "019de072-0f48-75dc-8e26-6c36719c246a",
  "docSlug": "59aa3600901f9a5fdbc1ca4ce261b5cc",
  "documentTitle": "Vigil Neuroscience | IPO Presentation Deck | 54 slides",
  "authorId": "vigil-neuroscience",
  "authorName": "Vigil Neuroscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 52,
  "pageCount": 54,
  "prevPage": 51,
  "nextPage": 53,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a checklist format to indicate progress, with the first item marked as completed.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-0f48-75dc-8e26-6c36719c246a/52",
  "deckHref": "/decks/019de072-0f48-75dc-8e26-6c36719c246a",
  "deckJsonHref": "/decks/019de072-0f48-75dc-8e26-6c36719c246a.json",
  "deckAnchorHref": "/decks/019de072-0f48-75dc-8e26-6c36719c246a#slide-52",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.78
      },
      "kind": "disclaimer",
      "text": "* The healthy volunteer single and multiple ascending dose trial is a first-in-human Phase 1 clinical trial... ** We expect to announce topline data... *** Will require an IND amendment to our open IND.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "554fc9f7-b494-4ba8-b4d9-c922349a646d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.94,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "list",
      "text": "Initiate first-in-human Phase 1 clinical trial with VGL101 in healthy volunteers* (Dec 2021); Select lead development candidate for small molecule TREM2 agonist program (Q1 2022); Announce topline data for Phase 1 clinical trial with VGL101 in healthy volunteers* (H2 2022); Initiate Phase 2 portion of the Phase 2/3 clinical trial with VGL101 in ALSP** (H2 2022); Initiate Phase 1b clinical trial with VGL101 in genetically defined AD patients with or without the relevant TREM2 variants (H2 2022); Initiate Phase 2 clinical trial with VGL101 in cALD*** (H1 2023)",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8bf263d-8b5f-499f-ba14-5c4c7749b759",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "And What Comes Next....",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "513895ec-a788-47c7-904d-a2d1f6f2593a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "b4a7aca2-6fac-4054-8dd6-6e913c74ff44",
      "evidence": "The slide presents a chronological sequence of project milestones.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}